COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,300 Articles (22,772 medRxiv, 8,528 bioRxiv)

Most recent first Previous |  Page 2910: Articles 29091-29100  | Next

CT in relation to RT-PCR in diagnosing COVID-19 in the Netherlands: a prospective study
Gietema, H. A., Zelis, N., Nobel, J. M., Lambriks, L. J. G., van Alphen, L. B., Oude Lashof, A. M. L., Wildberger, J. E., Nelissen, I. C., Stassen, P. M.
10.1101/2020.04.22.20070441 — Posted: 2020-04-24
A web-based Diagnostic Tool for COVID-19 Using Machine Learning on Chest Radiographs (CXR)
Gueguim Kana, E. B., Zebaze Kana, M. G., Donfack Kana, A. F., Azanfack Kenfack, R. H.
10.1101/2020.04.21.20063263 — Posted: 2020-04-24
Collateral damage: the impact on cancer outcomes of the COVID-19pandemic
Sud, A., Jones, M. E., Broggio, J., Loveday, C., Torr, B., Garrett, A., Nicol, D. L., Jhanji, S., Boyce, S. A., Ward, P., Handy, J. M., Yousaf, N., Larkin, J., Suh, Y.-E., Scott, S., Pharoah, P. D. P., Swanton, C., Abbosh, C., Williams, M., Lyratzopoulos, G., Houlston, R., Turnbull, C.
10.1101/2020.04.21.20073833 — Posted: 2020-04-24
Covid-19 and Inequity: A comparative spatial analysis of New York City and Chicago hot spots
Maroko, A. R., Nash, D., Pavilonis, B.
10.1101/2020.04.21.20074468 — Posted: 2020-04-24
Risk of drug-induced Long QT Syndrome associated with the use of repurposed COVID-19 drugs: a systematic review
Turgeon, J., Michaud, V., Dow, P., Al Rihani, S. R., Deodhar, M., Arwood, M., Cicali, B.
10.1101/2020.04.21.20066761 — Posted: 2020-04-24
ACE2 Homo-dimerization, Human Genomic variants and Interaction of Host Proteins Explain High Population Specific Differences in Outcomes of COVID19
Sharma, S., Singh, I., Haider, S., Malik, M. Z., Ponnusamy, K., Rai, E.
10.1101/2020.04.24.050534 — Posted: 2020-04-24 Discussion: Onsite
ACE2 polymorphisms and individual susceptibility to SARS-CoV-2 infection: insights from an in silico study
Calcagnile, M., Forgez, P., Iannelli, A., Bucci, C., Alifano, M., Alifano, P.
10.1101/2020.04.23.057042 — Posted: 2020-04-24
Validation of a SARS-CoV-2 spike ELISA for use in contact investigations and serosurveillance
Freeman, B., Lester, S., Mills, L., Rasheed, M. A. U., Moye, S., Abiona, O., Hutchinson, G., Morales-Betoulle, M., Krapinunaya, I., Gibbons, A., Chiang, C.-F., Cannon, D., Klena, J., Johnson, J. A., Owen, S. M., Graham, B. S., Corbett, K. S., Thornburg, N. J.
10.1101/2020.04.24.057323 — Posted: 2020-04-24
Evolution and molecular characteristics of SARS-CoV-2 genome
Bai, Y., Jiang, D., Lon, J. R., Chen, X., Hu, M., Lin, S., Chen, Z., Meng, Y., Du, H.
10.1101/2020.04.24.058933 — Posted: 2020-04-24 Discussion: Onsite
Genomic, geographic and temporal distributions of SARS-CoV-2 mutations
Yang, H.-C., Chen, C.-h., Wang, J.-H., Liao, H.-C., Yang, C.-T., Chen, C.-W., Lin, Y.-C., Kao, C.-H., Liao, J. C.
10.1101/2020.04.22.055863 — Posted: 2020-04-24

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).